文献速递腹部技术与安全CT

CT骨骼肌面积:确定最佳身高缩放指数并检验其死亡风险预测价值

Skeletal Muscle Area on CT: Determination of an Optimal Height Scaling Power and Testing for Mortality Risk Prediction.
PubMed 文献 · AJR Am J Roentgenol · 2023-10-25

本回顾性研究纳入16575例腹部CT患者,用自动软件测量L3骨骼肌面积,通过异速生长分析和身高独立性分析确定最佳身高缩放指数,并用Cox模型检验其对全因死亡预测的影响。结果显示最佳缩放指数约为1而非传统2,使用指数1时SMI预测死亡的C指数更高。

要点

  • L3骨骼肌面积的身高最佳缩放指数约为1,而非传统的身高平方。
  • 使用身高缩放指数1计算SMI时,预测全因死亡的C指数男性0.675、女性0.664。
  • 传统指数2的C指数男性0.663、女性0.653,指数1的预测效能更高。

核心结论

  • 研究结果支持在计算骨骼肌指数时使用身高缩放指数1,而非传统的指数2。

研究设计与样本

  • 回顾性研究,纳入16575例(男6985例,女9590例,平均年龄56.4岁)于2012年12月至2018年10月接受腹部CT的患者,使用自动软件测量L3骨骼肌面积,样本分为无主要疾病组5459例(用于确定最佳缩放指数)和有主要疾病组11116例(用于检验该指数)。

诊断标准与关键数值

  • 异速生长分析中,40岁及以下患者log(身高)回归系数男性1.02、女性1.08,40岁以上男性1.07、女性1.10(均p<.05 vs 回归系数2);身高独立性分析中,最佳缩放指数(相关系数最接近0)40岁及以下男性0.97、女性1.08,40岁以上男性1.03、女性1.09。

临床应用与阅片要点

  • 在CT体成分分析中,计算骨骼肌指数时可考虑采用身高缩放指数1而非传统的指数2,以提升全因死亡风险预测的判别能力(作者结论支持)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Sarcopenia is commonly assessed on CT by use of the skeletal muscle index (SMI), which is calculated as the skeletal muscle area (SMA) at L3 divided by patient height squared (i.e., a height scaling power of 2). OBJECTIVE. The purpose of this study was to determine the optimal height scaling power for SMA measurements on CT and to test the influence of the derived optimal scaling power on the utility of SMI in predicting all-cause mortality. METHODS. This retrospective study included 16,575 patients (6985 men, 9590 women; mean age, 56.4 years) who underwent abdominal CT from December 2012 through October 2018. The SMA at L3 was determined using automated software. The sample was stratified into two groups: 5459 patients without major medical conditions (based on ICD-9 and ICD-10 codes) who were included in the analysis for determining the optimal height scaling power and 11,116 patients with major medical conditions who were included for the purpose of testing this power. The optimal scaling power was determined by allometric analysis (whereby regression coefficients were fitted to log-linear sex-specific models relating height to SMA) and by analysis of statistical independence of SMI from height across scaling powers. Cox proportional hazards models were used to test the influence of the derived optimal scaling power on the utility of SMI in predicting all-cause mortality. RESULTS. In allometric analysis, the regression coefficient of log(height) in patients 40 years old and younger was 1.02 in men and 1.08 in women, and in patients older than 40 years old, it was 1.07 in men and 1.10 in women (all p < .05 vs regression coefficient of 2). In analyses for statistical independence of SMI from height, the optimal height scaling power (i.e., those yielding correlations closest to 0) was, in patients 40 years old and younger, 0.97 in men and 1.08 in women, whereas in patients older than 40 years old, it was 1.03 in men and 1.09 in women. In the Cox model used for testing, SMI predicted all-cause mortality with a higher concordance index using of a height scaling power of 1 rather than 2 in men (0.675 vs 0.663, p < .001) and in women (0.664 vs 0.653, p < .001). CONCLUSION. The findings support a height scaling power of 1, rather than a conventional power of 2, for SMI computation. CLINICAL IMPACT. A revised height scaling power for SMI could impact the utility of CT-based sarcopenia diagnoses in risk assessment.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Blankemeier L, Yao L, Long J, et al. Skeletal Muscle Area on CT: Determination of an Optimal Height Scaling Power and Testing for Mortality Risk Prediction. AJR Am J Roentgenol. 2023. PMID: 37877596. doi:10.2214/AJR.23.29889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。